We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Unizest are a trustworthy financial solutions for international students studying in the UK. The UK Aspire Account can be linked to the parents account abroad, and the currency exchange is transaction free. An account can be opened before students come to the UK and the card can be sent by courier to either your UK address or your home address.
days to go: Expired investment: £165,530
Gendius' has created intellin, an application through which people can track diabetes and make a good decision to reduce the risk of diabetes. It is on a mission to make sure that every person with diabetes knows their risk of complications and how to control them. The company has been launched across the EU with over 3,500 downloads in the EU and UK. In 2018, the company won £25K Momentum award to complete UX/UI research and, it has passed ISO27001. Recently, it has been invited to HIMSSHealth2.0 conference for the application's live demo.
days to go: Expired investment: £518,630
Chris James Mind Body is a premium health and lifestyle brand that offers a uniquely natural solution to help you acheive optimal levels of health and wellness all year round. Chris James has also created a 12 days cleanse plan as well as signing a book deal with the British publisher Penguin.
days to go: Expired investment: £60,500
Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £522,689
Simply rounding up the value of online purchases to the nearest pound and enabling users to save money into a digital wallet. Wishwallet aims to solve the problem of online shopping trolley abandonment, whereby consumers tend to leave products in their online baskets, but not continue to the checkout stage. The company aims to reduce this issue, whilst at the same time allowing customers to afford products and services they not have been able to before. Wishwallet's revenue stream is comprised of service fees to retailers, advertisements, recurring subscriptions and data. The company aims to launch their service with access to more than 1,500 retailers. They have already completed Phase 1 of their app development cycle and following this investment round, they aim to complete their product to be ready to launch in early 2019. Any additional contributions will be used for marketing campaigns, key hires and future app upgrades.
days to go: Expired investment: £122,140
AxiaFunder is a commercial litigation funding platform that offers investors access to pre-vetted cases. The platform aims to connect eligible investors like sophisticated retail investors, high-net-worth, and typically institutions with claimants seeking funding. Launched in January 2019 with the first case fully funded within seven days and the third in 7 hours; 5 cases financed to date, attracted over 355 registered investors so far including several institutions and has featured in several prominent publications including the Financial Times, Times and City AM. Also, they have won the 'Best Commercial Litigation Crowdfunding Platform 2019' award by Wealth & Finance. AxiaFunder plans to use the proceeds to make key hires particularly to strengthen its case origination, further development of its platform and marketing to build the AxiaFunder brand and grow its investor base.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £256,780
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph